NO20063469L - Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister - Google Patents
Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonisterInfo
- Publication number
- NO20063469L NO20063469L NO20063469A NO20063469A NO20063469L NO 20063469 L NO20063469 L NO 20063469L NO 20063469 A NO20063469 A NO 20063469A NO 20063469 A NO20063469 A NO 20063469A NO 20063469 L NO20063469 L NO 20063469L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- polyeheterocyclic
- receptor antagonists
- glutamate receptor
- metabotrophic glutamate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54529204P | 2004-02-18 | 2004-02-18 | |
PCT/US2005/005216 WO2005080386A1 (en) | 2004-02-18 | 2005-02-17 | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063469L true NO20063469L (no) | 2006-11-15 |
Family
ID=34886130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063469A NO20063469L (no) | 2004-02-18 | 2006-07-28 | Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister |
Country Status (20)
Country | Link |
---|---|
US (2) | US20070185100A1 (es) |
EP (1) | EP1716143A1 (es) |
JP (1) | JP2007523181A (es) |
KR (1) | KR20070052693A (es) |
CN (1) | CN1918154A (es) |
AR (1) | AR047966A1 (es) |
AU (1) | AU2005214378A1 (es) |
BR (1) | BRPI0507481A (es) |
CA (1) | CA2555272A1 (es) |
IL (1) | IL177058A0 (es) |
MX (1) | MXPA06009023A (es) |
NO (1) | NO20063469L (es) |
NZ (1) | NZ548693A (es) |
RU (1) | RU2381226C2 (es) |
SG (1) | SG149900A1 (es) |
TW (1) | TW200538179A (es) |
UA (1) | UA82434C2 (es) |
UY (1) | UY28764A1 (es) |
WO (1) | WO2005080386A1 (es) |
ZA (1) | ZA200606314B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1716143A1 (en) * | 2004-02-18 | 2006-11-02 | AstraZeneca AB | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
EP1809620B1 (en) * | 2004-11-04 | 2010-12-29 | Addex Pharma SA | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
NZ555320A (en) * | 2004-12-03 | 2010-11-26 | Schering Corp | Substituted piperazines as CB1 antagonists |
JPWO2006080533A1 (ja) * | 2005-01-31 | 2008-06-19 | 持田製薬株式会社 | 3−アミノ−1,2,4−トリアゾール誘導体 |
NZ564254A (en) * | 2005-05-18 | 2011-04-29 | Addex Pharma Sa | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
AR058807A1 (es) | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
HUP0500921A2 (en) * | 2005-10-05 | 2007-07-30 | Richter Gedeon Nyrt | Tetrazole derivatives, process for their preparation and their use |
TW200811137A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators II |
TW200808777A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGLUR5 modulators III |
TW200811156A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators IV |
TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
EP2170845A1 (en) * | 2007-06-28 | 2010-04-07 | Intervet International BV | Substituted piperazines as cb1 antagonists |
EP2170846A2 (en) * | 2007-06-28 | 2010-04-07 | Intervet International BV | Substituted piperazines as cb1 antagonists |
AR068921A1 (es) | 2007-10-19 | 2009-12-16 | Astrazeneca Ab | Derivados heterociclicos de tetrazol y 1,2-4 triazoles, composiciones farmaceuticas que los contienen y usos de los mismos para tratar desordenes neurologicos, gastrointestinales y del dolor,entre otros. |
TW200924774A (en) * | 2007-10-26 | 2009-06-16 | Astrazeneca Ab | Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mGluR5 |
WO2009054787A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5 |
WO2009054789A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,3-triazole pyrrolidine derivatives as modulators of mglur5 |
WO2009054792A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Aminopyridine derivatives as modulators of mglur5 |
TW200922586A (en) * | 2007-10-26 | 2009-06-01 | Astrazeneca Ab | Thiophene 1,2,4-triazole derivatives as modulators of mGluR5 |
WO2009054786A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
US8546576B2 (en) * | 2008-06-06 | 2013-10-01 | Sk Biopharmaceuticals Co., Ltd. | 3 or 4-substituted piperidine compounds |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
EP2414340A1 (en) * | 2009-04-03 | 2012-02-08 | Dainippon Sumitomo Pharma Co., Ltd. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
AU2010239253A1 (en) * | 2009-04-23 | 2011-11-24 | Merck Sharp & Dohme Corp. | 2-alkyl piperidine mGluR5 receptor modulators |
AR080055A1 (es) | 2010-02-01 | 2012-03-07 | Novartis Ag | Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1 |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
WO2014022752A1 (en) | 2012-08-03 | 2014-02-06 | Amgen Inc. | Macrocycles as pim inhibitors |
EP3008055B1 (en) * | 2013-06-11 | 2017-07-19 | F. Hoffmann-La Roche AG | Tetrazolone derivatives |
TWI802591B (zh) * | 2017-09-14 | 2023-05-21 | 日商第一三共股份有限公司 | 具有環狀構造的化合物 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL83275A (en) * | 1986-09-08 | 1994-02-27 | Novo Nordisk As | Compounds 1,2, 4-Oxadiazolyl Pipridine Transformed, their preparation and pharmaceutical preparations containing them |
US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US6953805B2 (en) * | 2001-01-05 | 2005-10-11 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
WO2003029210A2 (en) * | 2001-10-04 | 2003-04-10 | Merck & Co. Inc. | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
ATE486600T1 (de) * | 2002-03-12 | 2010-11-15 | Merck Sharp & Dohme | Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5 |
SE0201943D0 (sv) * | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New use |
EP1581525A2 (en) * | 2002-08-09 | 2005-10-05 | AstraZeneca AB | Compounds having an activity at metabotropic glutamate receptors |
EP1678169B1 (en) * | 2003-10-17 | 2009-07-22 | Astrazeneca AB | 4-(pyrazol-3-ylamino)pyrimidine derivatives for use in the treatment of cancer |
GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
EP1716143A1 (en) * | 2004-02-18 | 2006-11-02 | AstraZeneca AB | Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists |
TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
-
2005
- 2005-02-17 EP EP05713792A patent/EP1716143A1/en not_active Withdrawn
- 2005-02-17 UA UAA200608216A patent/UA82434C2/uk unknown
- 2005-02-17 SG SG200900931-7A patent/SG149900A1/en unknown
- 2005-02-17 TW TW094104643A patent/TW200538179A/zh unknown
- 2005-02-17 NZ NZ548693A patent/NZ548693A/en unknown
- 2005-02-17 MX MXPA06009023A patent/MXPA06009023A/es active IP Right Grant
- 2005-02-17 KR KR1020067015825A patent/KR20070052693A/ko not_active Application Discontinuation
- 2005-02-17 BR BRPI0507481-9A patent/BRPI0507481A/pt not_active IP Right Cessation
- 2005-02-17 US US10/588,754 patent/US20070185100A1/en not_active Abandoned
- 2005-02-17 CA CA002555272A patent/CA2555272A1/en not_active Abandoned
- 2005-02-17 AU AU2005214378A patent/AU2005214378A1/en not_active Abandoned
- 2005-02-17 JP JP2006554235A patent/JP2007523181A/ja active Pending
- 2005-02-17 RU RU2006127572/04A patent/RU2381226C2/ru not_active IP Right Cessation
- 2005-02-17 WO PCT/US2005/005216 patent/WO2005080386A1/en active Application Filing
- 2005-02-17 CN CNA2005800043398A patent/CN1918154A/zh active Pending
- 2005-02-18 UY UY28764A patent/UY28764A1/es unknown
- 2005-02-18 AR ARP050100612A patent/AR047966A1/es unknown
- 2005-02-18 US US11/060,561 patent/US20060025414A1/en not_active Abandoned
-
2006
- 2006-07-25 IL IL177058A patent/IL177058A0/en unknown
- 2006-07-28 ZA ZA200606314A patent/ZA200606314B/xx unknown
- 2006-07-28 NO NO20063469A patent/NO20063469L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
SG149900A1 (en) | 2009-02-27 |
UA82434C2 (uk) | 2008-04-10 |
UY28764A1 (es) | 2005-06-30 |
WO2005080386A1 (en) | 2005-09-01 |
US20060025414A1 (en) | 2006-02-02 |
NZ548693A (en) | 2010-05-28 |
EP1716143A1 (en) | 2006-11-02 |
AU2005214378A1 (en) | 2005-09-01 |
RU2006127572A (ru) | 2008-03-27 |
TW200538179A (en) | 2005-12-01 |
MXPA06009023A (es) | 2007-03-08 |
US20070185100A1 (en) | 2007-08-09 |
ZA200606314B (en) | 2007-12-27 |
RU2381226C2 (ru) | 2010-02-10 |
KR20070052693A (ko) | 2007-05-22 |
CA2555272A1 (en) | 2005-09-01 |
IL177058A0 (en) | 2006-12-10 |
JP2007523181A (ja) | 2007-08-16 |
BRPI0507481A (pt) | 2007-07-17 |
AR047966A1 (es) | 2006-03-15 |
CN1918154A (zh) | 2007-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063469L (no) | Polyeheterosykliske forbindelser og deres anvendelse som metabotrofe glutamat reseptorantagonister | |
NO20063470L (no) | Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister | |
NO20063468L (no) | Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister | |
NO20083909L (no) | Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere | |
NO20063599L (no) | Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
DK1716152T3 (da) | Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser | |
NO20074275L (no) | 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister | |
NO20050635L (no) | Nye tricykliske spiropiperidiner eller spiropyrrolidiner | |
NO20062677L (no) | Benzyleteraminforbindelser anvendbare som CCR-5-antagonister | |
NO20071504L (no) | Pyrimidinderivanter. | |
NO20071593L (no) | Pyrimidinderivater | |
NO20063597L (no) | Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister | |
NO20055977L (no) | Nye benzimidazolderivater | |
NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
NO20090760L (no) | Nye tricykliske spiropiperidinforbindelser, deres synteser og deres anvendelser som modulatorer av kemokinreseptor-aktivitet | |
NO20051223L (no) | Oksadiazoler som modulatorer av metabotropisk glutamat reseptor-5. | |
NO20092342L (no) | Azaspiroderivativater | |
NO20074592L (no) | Acetylenyl-pyrazolo-pyrimidinderivater som mGluR2-antagonister | |
NO20073019L (no) | Pyrasolonforbindelser som metabotrope glutamatreseptor-antagonister for behandlingen av nevrotiske og psykiatriske lidelser | |
NO20076638L (no) | Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
NO20070489L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
NO20083582L (no) | Pyridin-2-karboksamide derivater | |
NO20062533L (no) | 5-fluor, 5-klor- og cyanopyridin-2-yl-tetrazoler som ligander for den metabotrofe glutamatreseptor-5 | |
NO20062900L (no) | Nye forbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |